WEE1 and neoplasm: While studies in many cancer types, including ovarian [50], pancreatic cancer [67] and small cell lung cancers [68], have shown that combination treatment of pre-clinical models with both Wee1 kinase and PARP inhibitors are effective in inhibiting cell growth and/or decreasing tumor volume in vivo, these studies lack identification of biomarkers that could aid in patient selection for future clinical trials.